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NF-κBDiverse mechanisms are involved in the pathogenesis of β-cell failure in type 2 diabetes. Of them, the
accumulation of ceramide, a bioactive lipid metabolite, is suggested to play a major role in inﬂammatory and
stress responses that induce diabetes. However, the downstream inﬂammatory target of ceramide has not
been deﬁned. Using rat islets and the INS-1 β-cell line, we hypothesized that activation of the redox sensitive
protein TXNIP is involved in ceramide-induced β-cell dysfunction. Incubation of INS-1 cells and primary islets
with C2-ceramide (N-acetyl-sphingosine) downregulated insulin and PDX-1 expression and increased β-cell
apoptosis. Ceramide treatment induced a time dependent increase in TXNIP gene expression accompanied by
activation of nuclear factor (NF)-κB and reduced mitochondrial thioredoxin (TRX) activity. Pretreatment
with sulfo-N-succinimidyl oleate (SSO), an irreversible inhibitor of the scavenger receptor CD36, blocked
ceramide-induced up-regulation of TXNIP expression and activity of NF-κB. Blockade of NF-κB nuclear
translocation by the peptide SN50 prevented ceramide-mediated TXNIP induction. Furthermore, SSO also
attenuated ceramide-induced early loss of insulin signaling and apoptosis. Collectively, our results unveil
a novel role of CD36 in early molecular events leading to NF-κB activation and TXNIP expression.
These data suggest that CD36 dependent NF-κB-TXNIP signaling contributes to the ceramide-induced
pathogenesis of pancreatic β-cell dysfunction and failure.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Type 2 diabetes (T2D) is a heterogeneous syndrome resulting from a
progressive impairment of beta-cell insulin secretion and insulin
resistance in target tissues. In diabetic conditions, beta-cells are unable
to sustain a compensatory response, leading to beta-cell dysfunction
and death [1]. Impaired insulin secretion coupled to T2D is believed to
be caused by several abnormalities which include mitochondrial dys-
function, oxidative stress, ER stress, hyperglycemia (glucotoxicity), dys-
lipidemia (lipotoxicity), and the combination of both (glucolipotoxicity)
[2–8]. Studies with the Zucker diabetic fatty (ZDF) rat, an obesity-
induced diabetic animal model, indicate that elevated levels of FFA
cause ceramide accumulation which destroys beta-cells by apoptosis
[9]. Cellular ceramide content can also be increased via expression of in-
ﬂammatory cytokines [10,11]. Plasma ceramides are also increased in
genetically obese diabetic mice and obese subjects with T2D [12,13].
These observations suggest that ceramide accumulation plays a majorMedicine, YeungnamUniversity
05-703, South Korea.role in the development of diabetes. Furthermore, inﬂammatory
cytokine production caused by ceramide-induced activation of the
inﬂammasome leads to pulmonary edema [14].
Thioredoxin-interacting protein (TXNIP) affects the expression of
genes by altering the cellular redox state that links to ER stress,
inﬂammasome and beta-cell death [15–17]. TXNIP deﬁciency
protects against the mitochondrial death pathway but against
ER-stress-mediated lipoapoptosis [18]. Whether ceramide promotes
TXNIP expression in pancreatic beta-cell has not been determined. In
order to explore the effect of ceramide, it is tempting to speculate
that fatty acid transporter/cluster determinant 36 (FAT/CD36),
a class B scavenger receptor, may be involved in the induction of
beta-cell dysfunction by ceramide. CD36 binds a variety of ligands in-
cluding FFA, functions in many different biological processes, and is
localized in the secretory granules of beta-cells [19,20]. Forced
expression of CD36 in beta-cells increases the uptake of fatty
acids and leads to metabolic and functional alterations [21,22].
Furthermore, CD36 initiates inﬂammatory signaling in adipocytes
and macrophages in diet-induced obesity and hyperlipidemias
[23].Therefore, it was investigated whether CD36 mediates TXNIP
activation and the subsequent induction of beta-cell dysfunction
by ceramide.
Fig. 2. Ceramide effect onmitochondrial dysfunction. (a) INS-1 cells were treatedwith C2-ceramide for 3 h andmitochondrial membrane potential was analyzed by FACs using DiO6 dye.
(b–c) INS-1 cells were treated with indicated concentrations of C2-ceramide and inactive analog of C2-ceramide (C2-dihydroceramide) for 24 h. Representative protein expression of
cytochrome c in cytosol and cleaved caspase 3 were analyzed byWestern blot. β-Actin used as a loading control. (d) Cellular ROS production was detected by ﬂuorescence microscopy
using 10 μM/L DCF-DA. (e) Cells were treated with C2-ceramide (50 μM) for different time periods and phospho form of JNK, p38MAPK was analyzed by Western blot analysis. Equal
loading was conﬁrmed by using β-actin. Results are presented as means ± SEM of three independent experiments. *P b 0.005 vs control.
Fig. 1. Effects of ceramide on beta-cell apoptosis, insulin and PDX1 gene expression. (a) INS-1 cells were treated with indicated concentrations of C2-ceramide and inactive
analog of C2-ceramide (C2-dihydroceramide) for 24 h, and apoptosis was assessed by ﬂuorescence microscopy. Data represent means ± SEM of three independent experiments.
*P b 0.05 and **P b 0.001 vs control. (b) Rat islet cells were treated with C2-ceramide (50 μM) for 24 h, and death was assessed by ﬂuorescence microscopy. *P b 0.005 vs control.
(c, d) INS-1 cells were treated with C2-ceramide for 24 h. Insulin and PDX1 mRNA levels were quantiﬁed by real-time RT-PCR. Results are presented as means ± SEM of three
independent experiments. *P b 0.05 vs control (c); *P b 0.001 vs control (d).
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2.1. Cell culture, chemicals
The INS-1 rat insulinoma cell line (INS-1) was cultured in 5% CO2 at
37 °C in RPMI 1640 (Life Technologies, Inc., Grand Island, NY) medium
supplemented with 10% fetal bovine serum (FBS) (Gibco, Grand Island,
NY, USA), 100 units/mL penicillin, and 100 μg/mL streptomycin.
Pancreatic islets were isolated from male Sprague–Dawley rats by
collagenase digestion, handpicked and dispersed in an RPMI medium.
C2-ceramide and C2-dihydroceramide and DiOC6 were purchased
from Sigma-Aldrich (St. Louis, MO, USA), sulfo-N-succinimidyl
oleate (SSO) from Cayman Chemical (Ann Arbor, MI, USA).NF-κB in-
hibitor (sc-3060) was obtained from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA).
2.2. Apoptosis and mitochondrial functional assay
Apoptosis was determined by TUNEL in-situ cell death detection kit
(Roche, Basal, Switzerland). Brieﬂy, cells were serum starved and then
treated with various doses of C2-ceramide and C2-dihydroceramide
(D2-ceramide) (50 μM) for 24 h. Islets was treated with C2-ceramide
(50 μM) for 24 h. Upon completion of treatment, cells were processed
further, according to the manufacturer's instructions and image was
captured using ﬂuorescence microscopy. Percentage of cell death was
quantiﬁed by ImageJ software (National Institutes of Health). For
the analysis of mitochondrial membrane potential, cells were treated
with C2-ceramide (50 μM) for 3 h and then labeled with 10 nM DiOC6
for 5 min at 37 °C. After incubation, the cells were washed once and
resuspended in PBS for ﬂow cytometry. Cellular reactive oxygen
species were measured using the peroxide sensitive ﬂuorescent probeFig. 3. Ceramide induces TXNIP mRNA, protein expression and reduces thioredoxin activity. (a
by RT-PCR. TXNIPmRNA increases as early as 3 h of incubationwith C2-ceramide. *P b 0.005 an
of TXNIP was measured by immunoblotting. Relative protein units were calculated with refere
was visualized using mitochondrion-selective probe CMXRos. (d) Thioredoxin activity was m
means ± SEM of three independent experiments. *P b 0.005 vs ceramide.2, 7-dichlorodihydroﬂuorescein diacetate (DCF-DA; Molecular Probes,
Carlsbad, CA, USA). Upon completion of treatment, cells were washed
with PBS and then incubated in the dark for 15 min with 10 μM/L
DCF-DA at 37 °C, and then visualized under a ﬂuorescence microscope.
ROS levels were calculated as percentage increases versus control.
Mitochondrial dysfunction and apoptosis were also conﬁrmed
by Western blot analysis of cytochrome c release and cleaved caspase
3 activation. Mitochondrial localization of TXNIP was visualized using
mitochondrion-selective probe CMXRos (200 nM ﬁnal concentration;
MitoTracker Red, Molecular Probes, Eugene, OR).
2.3. Real-time PCR
Total RNA was isolated using a TRIzol reagent (Invitrogen, Carlsbad,
CA, USA) and reverse-transcribed using the First strand cDNA synthesis
kit (Fermentas, Vilnius, Lithuania) according to the manufacturer's
instructions. Real-time PCR was performed using speciﬁc gene primers:
5′ - ACCCAAGTCCCG TCG TGAAGT - 3′ (forward) and 5′ - CCAGTTGGT
AGA GGG AGC AGA TG - 3′ (reverse) for insulin; 5′ - GGC TTA ACC TAA
ACG CCA CA - 3′ (forward) and 5′ - GGG ACC GTC CAA GTT TGT AA - 3′
(reverse) for pancreatic duodenal homeobox-1 (PDX-1); and 5′ - CGAG
TCAAAGCCGTCAGGAT - 3′ (forward) and 5′ - TTCATAGCGCAAGTAGTC
CAAGGT - 3′ (reverse) for TXNIP. Transcript values were normalized
to a signal obtained with the β-actin and expressed as fold differences
versus controls.
2.4. NF-κB-p65 DNA-binding activity
Activation of the NF-κB complex was quantiﬁed by using an ELISA-
based Cayman's p65 transcription factor assay (Cayman Chemicals,
AnnArbor,MI, USA). Brieﬂy, oligonucleotides that contained a consensus) TXNIP expression was regulated by C2-ceramide in a time dependent manner measured
d **P b 0.001 vs control. Results are expressed asmeans± SEM. (b) The protein expression
nce to β-actin. *P b 0.01 and **P b 0.005 vs control. (c) Mitochondrial localization of TXNIP
easured by insulin reduction assay after C2-ceramide treatment for 6 h. Data represent
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with nuclear extracts. The plate was washed extensively according to
the manufacturer's instructions and incubated with a speciﬁc primary
antibody, followed by a secondary antibody conjugated to horseradish
peroxidase (HRP) that was used to provide a sensitive colorimetric
readout at 450 nm. Nuclear extract was fractionated using the NE-PER
nuclear and cytoplasmic extraction reagent kit (Thermo Fisher Scientiﬁc
Inc., Rockford, USA) according to the instructions of the supplier.
2.5. Thioredoxin activity
The mitochondrial fraction was extracted using a mitochondria
isolation kit (Thermo Fisher Scientiﬁc) according to the manufacturer's
instructions. The protein concentrationwas obtained using the Bradford
protein assay. Thioredoxin activity in cell lysates was measured by the
method of Chen et al. [24].
2.6. Western blotting
Protein lysates were prepared using a lysis buffer (20 mM/L Tris,
pH 7.4, 10 mM/L Na4P2OH, 100 mM/L NaF, 2 mM/L Na3VO4, 5 mM/L
EDTA, pH 8.0, 0.1 mM/L PMSF, 1% NP-40) containing proteinase and
phosphatase inhibitors. Proteinswere resolved by running on aNuPAGE
4–12% Bis–Tris gel (Invitrogen) and transferred to PVDF membranes
(Millipore, Billerica, MA, USA). After blocking, the membranes wereFig. 4. Ceramide effect on NF-κB activation. (a) INS-1 cells were treated with C2-ceramide (50
analyzed by immunoblotting. IL1β used as a positive control. *P b 0.01; **P b 0.005; #P b 0.0
(blue) were examined using a confocal microscope. *P b 0.01 vs 1 h (c) The DNA-binding ac
treatment for 90 min. Results are expressed as means ± SEM. *P b 0.001 vs control.incubated with primary antibodies: phospho JNK, total JNK, phospho
p38 MAPK, total p38 MAPK, cleaved caspase 3, phospho AKT, total
AKT, phospho p65 (Cell Signaling Technology, Danvers, MA, USA),
total p65 (Santa Cruz, Dallas, TX, USA), TXNIP, thioredoxin, and
actin (Abcam, Cambridge, UK), followed by washing and incubated
with horseradish peroxidase (HRP)-conjugated secondary antibodies.
Immunoreactive proteins were detected using ECL reagents (ECL Plus;
Amersham, GEHealthcare Life Sciences, Little Chalfont, Buckinghamshire,
UK). Band densities were measured using ImageJ software (NIH).
2.7. Immunoﬂuorescence
Cellswereﬁxed in 2%paraformaldehyde for 15min and then perme-
abilized with 0.2% Triton X-100 for 15 min at room temperature.
Phospho NF-κB-p65 primary antibody was applied overnight and then
was incubated for 1 h with the secondary antibody Alexa-Fluor488
(Invitrogen, Eugene, OR, USA). Cellswere observed through anOlympus
Fluoview™ FV1000 confocal microscope. Immunoﬂuorescence images
were quantiﬁed by ImageJ software (NIH).
2.8. Determination of insulin content
Intracellular insulin content was measured by using a rat insulin
radioimmunoassay kit (Millipore; EZRMI-13K, Billerica, MA) according
to the manufacturer's instructions.μM) for different time periods and expression of phospho-P65 and total form of P65 was
05 vs control (b) The cellular localization of phospho-P65 and nuclei stained with DAPI
tivity of p65 was measured by enzyme-linked immunosorbent assay after C2-ceramide
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Statistical signiﬁcance was determined with the Student's t-test or
by analysis of variance (ANOVA) as appropriate. P b 0.05 was deﬁned
as statistically signiﬁcant. All experimentswere repeated independently
three or more times.
3. Results
3.1. Induction of beta-cell apoptosis by ceramide
C2-ceramide induced a concentration-dependent apoptotic re-
sponse in beta-cells (Fig. 1a). D2-ceramide, an inactive ceramide analog,
was not effective. C2-ceramide (50 μM) also induced a cytotoxic effect
in isolated rat islets (Fig. 1b). Ceramide-induced downregulation
of beta-cell survival was associated with suppression of insulin mRNA
and PDX1 mRNA expression (Fig. 1c–d). Ceramide also induced a
signiﬁcant loss of total cellular insulin content compared with controls
(Supplement Fig. 1).
3.2. Induction of mitochondrial dysfunction by ceramide
Treatment of INS-1 cells with C2-ceramide caused a collapse in
the mitochondrial membrane potential (Δψ) followed by a release of
cytochrome c into the cytosol, reﬂecting the activation of the permeabil-
ity transition pore (PTP), a key event in mitochondrial-dependent
apoptotic cell death (Fig. 2a–b). Release of cytochrome c into the cytosol
leads to caspase-3 activation (Fig. 2c). Furthermore, the total intracellu-
lar ROS level, a crucial factor promoting beta-cell apoptosis, was
increased by C2-ceramide (Fig. 2d). Consistent with this ﬁnding,
C2-ceramide treatment increased the activation of stress kinases JNKFig. 5. Effect of CD36 inhibition on ceramide induced NF-κB activation. (a) CD36 inhibitor SSO in
and then exposed to C2-ceramide for indicated time periods. Expression of phospho-P65 was a
pretreatment inhibits phospho-p65 nuclear localization examined by a confocal microscope af
C2-ceramide induced p-P65DNA-binding activity. Brieﬂy, cells were pretreatedwith SSO (200 μ
90min. DNA-binding activity of NF-κB p-P65wasmeasured by ELISA. Values representmeans±
post hoc test. *P b 0.001 vs control; #P b 0.001 vs ceramide and **P b 0.001 vs SSO.and P38 MAPK (Fig. 2e) but not ERK (data not shown). These ﬁndings
suggest that ceramide induces apoptosis by inducing mitochondrial
dysfunction.
3.3. Induction of TXNIP expression and inhibition of thioredoxin by
ceramide
Treatment of INS-1 cells with C2 ceramide increased the expression
of TXNIP (Fig. 3a) without any change in the expression levels of
thioredoxin (Fig. 3b). However, thioredoxin plays a vital role in
redox imbalance induced by mitochondrial stress by repairing the
reduction of proteins by cysteine thiol–disulﬁde exchange. To clarify
whether ceramide-induced TXNIP regulates thioredoxin activity,
mitochondrial shuttling of TXNIP was assessed with MitoTracker
Red, a mitochondria-speciﬁc probe, by immunoﬂuorescence (Fig. 3c).
Ceramide treatment induced mitochondrial localization of TXNIP with
inhibition of thioredoxin activity (Fig. 3d). Therefore, ceramide-induced
activation of TXNIP induced a negative redox balance by negatively
regulating thioredoxin activity.
3.4. Activation of NF-κB by ceramide
We speculated that ceramide-induced up-regulation of TXNIP
expression was associated with increased NF-κB activation, an
important nuclear transcription factor in the regulation of both the
inﬂammatory response and cell survival. Ceramide-treated INS-1
cells showed an early increased level of phospho-NF-κB-p65 with
nuclear translocation of the p-p65 subunit conﬁrmed by Western
blot and immunoﬂuorescence analysis (Fig. 4a–b). Additionally,
elevated DNA binding and transcriptional activities of p-NF-κB-p65
were observed by ELISA-based transcription factor assay (Fig. 4c).hibits ceramide-induced p-P65 activation. Cells were pretreatedwith SSO (200 μM) for 1 h
nalyzed by immunoblotting.*P b 0.005 vs control; **P b 0.05 vs ceramide (b) SSO (200 μM)
ter 1 h of C2-ceramide treatment. (c) Effect of SSO (200 μM) and NF-κB inhibitor SN50 on
M) and NF-κB inhibitor peptide SN50 (36 μM) for 1 h and then exposed to C2-ceramide for
SEM and statistical signiﬁcance was determined by one-way ANOVA followed by Tukey's
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by ceramide imply that ceramide-induced NF-κB acts upstream
of TXNIP expression, in contrast to the report that TXNIP induces
NF-κB in retinal capillary endothelial cells under diabetic condi-
tions [25]. In keeping with this view, ceramide-induced NF-κB
activation evoked a signiﬁcant pro-apoptotic role in beta-cells.
3.5. Inhibition of CD36 prevents ceramide-induced NF-κB activation and
reduces TXNIP expression
The irreversible CD36 inhibitor sulfo-N-succinimidyl oleate (SSO)
inhibited ceramide-induced activation and nuclear translocation of
NF-κB (Fig. 5a–b). We further characterized SSO effect on NF-κB DNA
binding activity. As shown in Fig. 5c, SSO treatment signiﬁcantly
decreased NF-κB DNA binding activity in ceramide-treated cells. In
addition, a cell permeable NF-κB inhibitor peptide SN5O blocked
NF-κB activity by ceramide.
We hypothesized that if SSO blocked ceramide stimulated NF-κB,
then the expression of TXNIP should be inhibited. As predicted, SSO
(200 μM) pretreatment rapidly decreased the TXNIP mRNA expres-
sion levels compared with ceramide-treated cells at different time
periods (Fig. 6a). In addition, TXNIP protein translation was also
decreased by SSO treatment (Fig. 6b). Furthermore, we examined
the possibility that TXNIP-mediated decrease in thioredoxin activity
would be prevented by SSO treatment. Similarly, thioredoxin activity
was markedly recovered from SSO-treated cells as compared withFig. 6. Inhibitory effect of SSO on ceramide induced TXNIP mRNA, protein and thioredoxin act
represent the mean ± SEM of three independent measurements. #P b 0.05 vs control; *P b 0.05
by two-way ANOVA followed by Tukey's post hoc test. (b) Inhibition of CD36 reduced ceramide
experiments. *P b 0.05 vs control, #P b 0.05 vs ceramide (c) SSO pretreatment prevents ceramide
and then exposed to C2-ceramide for 6 h. Results are expressed as means± SEM. *P b 0.05 vs co
ceramide-induced TXNIP mRNA. Results are presented as means ± SEM of three independen
treatment condition and (e) SN50 blocks ceramide induced TXNIP protein expression. Values
determined by two-way ANOVA followed by Tukey's post hoc test. **P b 0.05 vs control, #P b 0ceramide-treated cells (Fig. 6c). To a similar extent, pretreatment
of cells with SN50 signiﬁcantly reduced ceramide-induced TXNIP
gene expression (Fig. 6d).Moreover, TXNIP protein expression was
also reduced by SN50 treatment (Fig. 6e). Taken together, these
results demonstrate that ceramide-mediated TXNIP expression was
regulated by CD36–NF-κB pathways.
3.6. Inhibition of CD36 prevents ceramide-induced TXNIP expression on
islet cells
Pretreatment of isolated islets with SSO inhibited ceramide-induced
TXNIP expression in a time dependent manner (Fig. 7a) to a similar
extent to that observed in INS-1 cells. SSO treatment signiﬁcantly
decreased TXNIP protein expression (Fig. 7b). Taking together, our
results suggest that CD36 signaling contribute to ceramide-induced
beta cell dysfunction.
3.7. Inhibition of CD36 prevents the reduction of insulin, PDX1 mRNA and
apoptosis by ceramide
In an attempt to establish the effects of ceramide on insulin signaling
events, Akt activity was measured. An inverse correlation between
ceramide and Akt activity has been documented in several studies
[26–29]. To this end, INS-1 cells were treated with SSO and then ex-
posed to ceramide. SSO pretreatmentmarkedly restored the Akt activity
(Fig. 8a). SSO also signiﬁcantly reversed the inhibitory effect of ceramideivities. (a) Inhibition of CD36 blocks ceramide-induced expression of TXNIP mRNA. Data
;**P b 0.005 compared with ceramide under the same treatment condition as determined
-induced TXNIP protein expression. Values representmeans ± SEM of three independent
-induced reduction of thioredoxin activity. Cellswere pretreatedwith SSO (200 μM) for 1 h
ntrol; #P b 0.05 vs relative ceramide-treated group. (d) Inhibition of NF-κB by SN50 blocks
t experiments. #P b 0.05 vs control; **P b 0.005 compared with ceramide under the same
represent means ± SEM of three independent experiments. Statistical signiﬁcance was
.05 vs relative ceramide-treated group.
Fig. 7. Inhibition of CD36 blocks ceramide-induced TXNIP mRNA and protein expression
in rat islets. (a) Rat islet clusters were isolated and treated with C2-ceramide (50 μM) in
the presence or absence of SSO (500 μM) for the indicated time points. TXNIP gene
expression was assessed by RT-PCR. Data are expressed as means ± SEM. *P b 0.05 vs
control; #P b 0.005, **P b 0.001 vs relative ceramide-treated group as determined by
two-way ANOVA followed by Tukey's post hoc test. (b) Isolated islets were pretreated
with SSO (500 μM) for 1 h and then exposed to C2-ceramide for the indicated time points.
The cell lysates were analyzed by Western blotting with TXNIP or β-actin antibodies.
Results are presented as means ± SEM of three independent experiments. *P b 0.005 vs
control; #P b 0.001 vs ceramide-treated group.
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to correlate the effects of SSO on beta cell survival. Interestingly, SSO
treated cells had a much smaller apoptotic response to ceramide, con-
comitant with a marked inhibition of cleaved caspase 3 expression
(Fig. 8d–e). Together, these results suggest that CD36 plays a key role
in ceramide-induced beta-cell apoptosis.
4. Discussion
In this study, we demonstrated for the ﬁrst time that ceramide in-
duces the expression of TXNIP, an endogenous inhibitor of thioredoxin
in pancreatic beta cells. CD36 initiated activation of NF-κB acts as a
critical factor in ceramide-induced TXNIP expression. Furthermore,
blockade of CD36 increases insulin signaling and prevents the
development of β-cell failure.
Overwhelming evidence suggests that abnormal ceramide signaling
plays a critical role in the pathophysiology of beta-cell failure during
T2D. In agreement with what has been previously found, we observed
an apoptotic response to ceramide in the pancreatic beta cell line as
well as isolated islet cells. The inactive ceramide analog (D2-ceramide)
failed to induce an apoptotic effect. The results of multiple studies
with diverse cell lines, in rat and mouse islet preparations, and more
importantly in human islet cells, also link endogenous production and
accumulation of ceramide to increased rates of apoptosis [30–32].
Additionally, we found reduced insulin gene expression by ceramide
accompanied with the reduction of PDX1 mRNA expression, a critical
regulator of insulin gene expression as well as beta-cell development,
differentiation and survival. In line with this, Kelpe et al. [33] found
the generation of ceramide through the action of palmitate-reduced
insulin gene expression. With this functional characterization, we also
tested the effect of ceramide on intracellular insulin content in INS-1
aswell as in isolated beta-cells. Of note, the intracellular insulin content
was signiﬁcantly decreased in insulin producing cells, suggesting pro-
nounced cytotoxic effects of ceramide (Supplement 1). Most strikingly,
it is closely integrated with mitochondria, which play an important role
in apoptotic cell death by multiple stimuli. Ceramide substantially
reduced themitochondrial membrane potential followed bymitochon-
drial release of cytochrome c, reﬂecting activation of the mitochondrial
permeability transition fore (PTP), leading to the death of the beta-cell.
Under the same conditions, ceramide induced the accumulation of
intracellular reactive oxygen species (ROS) which are known to be
cytotoxic and to rapidly activate stress kinases.
In response to oxidative stress, TXNIP translocates to mitochondria
where it directly binds to and inhibits the anti-oxidative protein
thioredoxin, causing an increase in beta-cell apoptosis through the
intrinsic mitochondrial death pathway [34]. In contrast, our data show
that ceramide-induced TXNIP mRNA expression associates with the in-
creased TXNIP protein expression in the mitochondria with reduced
thioredoxin activity. Given that TXNIP expression is related to a diverse
number of pathological functions, the identiﬁcation of molecules that
can modulate TXNIP expression in response to ceramide requires
further study. Identiﬁcation of suchmolecules may lead to the develop-
ment of a new drug target. In this context, it is interesting to note that
ceramide-induced activation of NF-κB is accompanied by increased
TXNIP expression.
Ceramide causes NF-κB activation [35,36]. Studies also suggest that
TXNIP contains binding sites for NF-κB [37]. Induction of TXNIP expres-
sion by glucocorticoid is mediated by p38/MAPK in beta-cell death [38].
It is likely that P38/MAPK levels rise in response to ceramide and inhibi-
tion of p38/MAPK does not inhibit TXNIP induction (Supplement 3).
Therefore, activation of NF-κB is thought to be a critical factor contribut-
ing to the induction of TXNIP expression by C2-ceramide in beta-cells.
Recent studies in monocytes showed that palmitate-induced
expression of CD36 enhances ceramide accumulation [39]. We
found that treatment with C2-ceramide increased CD36 protein
levels (Supplement 2). In addition, CD36 is increased in rodentmodels of insulin resistance and in skeletal muscle of obese humans
[40,41]. Moreover CD36-deﬁcientmacrophages have reducedNF-κB ac-
tivation and reduced release of interleukin (IL)-1b and tumor necrosis
factor (TNF)-α [42]. We show that SSO inhibits ceramide-induced
TXNIP expression. Interestingly, inhibition of CD36 by SSO signiﬁcantly
reduced ceramide-induced NF-κB activation which is upstream of
TXNIP induction. Along these lines, inhibition of NFκB active complex
nuclear translocation by the cell-permeable peptide SN-50 signiﬁcantly
prevented ceramide-induced TXNIP expression. Consistent with our
ﬁndings, previous reports provide evidence correlating reduced levels
of activated NF-κB in CD36-knock-out mice and monocyte-derived
macrophages from CD36-deﬁcient patients [43,44]. Interestingly,
inhibition of CD36 by SSO reduced TXNIP protein expression with the
signiﬁcant restoration of mitochondrial thioredoxin-2 activity. Further-
more, mitochondrial membrane potential loss was partially recovered
by SSO (data not shown).
A recent study by Vandanmagsar et al. [45] reported that lipotoxicity-
associated increases in intracellular ceramide induce caspase-1 cleavage
in macrophages and adipose tissue through NLRP3 inﬂammasome
Fig. 8. Representative Western blots showing protein expression of (a) phospho and total form of Akt after C2-ceramide and SSO treatment. SSO was added 1 h prior to the incubations
with C2-ceramide. *P b 0.005 vs control; #P b 0.001 vs ceramide. (b–c) SSO treatment attenuated ceramide reduced insulin and PDX1 gene expression. *P b 0.001 vs control; **P b 0.05 vs
ceramide. (d) Inhibition of CD36 by SSO attenuates ceramide-induced apoptosis. INS-1 cells were treated with SSO for 1 h and then exposed to C2-ceramide for another 24 h. Cell death
was assessed by ﬂuorescencemicroscopy. Values represent means± SEM. *P b 0.01 vs control; **P b 0.05 vs ceramide. (e) Cleaved caspase 3 was analyzed byWestern blot. *P b 0.005 vs
control; **P b 0.001 vs ceramide-treated group.
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producing IL-1β through NLRP3 inﬂammasome activation under ER
stress [16]. Moreover, a recent study by Shetty et al. [46] showed
that an early CD36-mediated pathogenic inﬂammasome activation
links cholesterol accumulation to the chronic inﬂammatory process
of atherosclerosis. So, future studies are warranted that examine
the relationship between CD36 and NLRP3 inﬂammasome activation
in the pancreatic beta cell dysfunction and failure. In addition, proper
beta-cell function is dependent on insulin signaling. Akt/PKB expres-
sion is reduced by ceramide [47–50]. Taking this into account, we
found that ceramide inhibited Akt activation in a time dependent
manner while SSO blocked this inhibition. This suggests that Akt
activity is important for survival of pancreatic beta-cells. Activation
of Akt/PKB directly regulates members of the Bcl-2 family and
decreases the percentage of apoptotic cells by ceramide [51]. In
addition, activation of Akt/PKB inhibits early apoptotic events by
maintaining mitochondrial integrity [52]. In view of these, activation
of mitochondrial signaling may enhance the release of pro-apoptotic
factors which may contribute to the induction of apoptosis and
downregulation of insulin and PDX1 expression by ceramide.
Reduction of CD36 signaling by SSO dampens the oxidative stress
dependent signals and increases cell survival.
In conclusion, we highlight the importance of CD36-mediated
intracellular signaling in the development of ceramide-induced TXNIP
expression and β-cell failure. Our data demonstrate that the inhibition
of CD36 reduced ceramide-induced mitochondrial stress, which acts
as a major driving force in the progression of T2D. Furthermore, block-
ade of CD36 increases insulin signaling and prevents the developmentof β-cell failure. Collectively, this study provides direct evidence that
activation of the CD36 signaling in ceramide-induced TXNIP expression
is a critical trigger in causing pancreatic damage. Future studies are
warranted to determine if CD36 activation is involved in beta-cell
inﬂammasome activation toward type 2 diabetes.
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